Helping you developbiologics faster and easierfor patients in need
Deep knowledge ofpre-clinical technologiesand methods
In-depth experience from gene synthesis and subcloning to protein expression and purification.
Proven track record for a broad range of in vitro and in vivo models of disease.
Short timelines and high titers at every development stage with RapTr™ CLD services.
Relive our June 20th webinar! Instant Replay
SDBN “Lunch On Us” Event
San Diego, CA
Proclara Biosciences Presents New Preclinical Data Supporting the Development of NPT189
Lung Therapeutics Announces Series B Funding
…a solid performer for my company’s animal studies…
Elisabeth Gardiner, PhD Chief Scientific Officer Meditope Biosciences, Inc.
GVK BIO announces the appointment of Axel Schleyer, Ph.D. as Chief Executive Officer, Aragen Bioscience, Inc.
Aragen Bioscience Expands RapTr Cell Line Development Services
Aragen Bioscience Announces AAALAC Accreditation
RapTr Cell Line Development Services Introduced